atherosclerotic cardiovascular disease
atherosclerotic cardiovascular disease
Explore linked clinical trials. Standard reference: MONDO:106013427 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure | Arterial Occlusive Diseases, Disease Attributes, Genetic Risk Score, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, disease susceptibility, hypertensive disorder, inherited disease susceptibility, vascular disorder | Recruiting | Not applicable | 2026-10-09 | NCT06962488 | |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | Arterial Occlusive Diseases, Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, nutritional disorder, obesity disorder, overnutrition, vascular disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07037433 | |
| Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Followed by an Open-label Patient Cohort | Arterial Occlusive Diseases, acute coronary syndrome, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Early phase 1 | 2026-09-25 | NCT06813339 | |
| Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Recruiting | Not stated | 2026-09-24 | NCT07594392 | |
| AI-CCTA for Predicting Cardiovascular Events in CAD | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Active, not recruiting | Not stated | 2026-09-21 | NCT07832175 | |
| A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-08 | NCT07551492 | |
| Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorder | Active, not recruiting | Phase 3 | 2026-08-25 | NCT05030428 | |
| Pelacarsen Roll-over Extension Program | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Recruiting | Phase 3 | 2026-07-29 | NCT06875973 | |
| VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorder | Active, not recruiting | Phase 4 | 2026-07-29 | NCT06249165 | |
| Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease | Arterial Occlusive Diseases, Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, brain disorder, cardiovascular disorder, carotid artery disorder, carotid stenosis, central nervous system disorder, cerebrovascular disorder, chronic renal failure syndrome, coronary artery disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, hypertensive disorder, kidney disorder, kidney failure, metabolic disease, myocardial ischemia, nervous system disorder, peripheral arterial disease, peripheral vascular disease, type 2 diabetes mellitus, urinary system disorder, vascular disorder | Not yet recruiting | Phase 4 | 2026-07-15 | NCT07704190 | |
| A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab | Arterial Occlusive Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, familial hypercholesterolemia, hereditary disease, hyperlipidemia, hyperlipoproteinemia, inborn errors of metabolism, metabolic disease, vascular disorder | Recruiting | Not stated | 2026-07-15 | NCT07543731 | |
| Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial | Arterial Occlusive Diseases, Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, metabolic disease, vascular disorder | Recruiting | Not applicable | 2026-07-07 | NCT05705804 | |
| The Belgian REAL (BE.REAL) Registry | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Active, not recruiting | Not stated | 2026-06-02 | NCT05726838 | |
| Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia | Arterial Occlusive Diseases, Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, metabolic disease, vascular disorder | Recruiting | Phase 4 | 2026-05-04 | NCT07034690 | |
| A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-05-01 | NCT03705234 | |
| Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease | Arterial Occlusive Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, familial hypercholesterolemia, hereditary disease, hyperlipidemia, hyperlipoproteinemia, inborn errors of metabolism, metabolic disease, vascular disorder | Enrolling by invitation | Not stated | 2026-04-08 | NCT06112327 | |
| Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-02-27 | NCT05581303 | |
| Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus | Arterial Occlusive Diseases, Body Weight, Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, Obesity, Abdominal, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, metabolic disease, nutritional disorder, obesity disorder, overnutrition, prediabetes syndrome, vascular disorder | Active, not recruiting | Phase 4 | 2025-12-31 | NCT05749874 | |
| Fish Oil, Metformin and Heart Health in PCOS | Arterial Occlusive Diseases, Cardiac Hypertrophy, Cardiomegaly, Hypertrophy, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Atherosclerotic, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, heart disorder, polycystic ovary syndrome, vascular disorder | Recruiting | Phase 1 | 2025-12-12 | NCT06424860 | |
| Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Recruiting | Not stated | 2025-08-03 | NCT06858332 | |
| A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Recruiting | Not applicable | 2025-05-06 | NCT06571162 | |
| The Prevent Coronary Artery Disease Trial | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Recruiting | Phase 3 | 2025-04-29 | NCT06494501 | |
| Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease | Arterial Occlusive Diseases, Carotid Atherosclerosis, Digestive System Diseases, Gastrointestinal Hemorrhage, Hemorrhage, Infarction, Intracranial Hemorrhages, Necrosis, Pathologic Processes, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Atherosclerotic, Signs and Symptoms, Signs and Symptoms, Digestive, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, brain disorder, cardiovascular disorder, carotid artery disorder, carotid stenosis, central nervous system disorder, cerebrovascular disorder, coronary artery disorder, digestive system disorder, duodenal disorder, duodenal ulcer, dyspepsia, gastric ulcer, heart disorder, intestinal disorder, intracerebral hemorrhage, ischemic disease, ischemic stroke, myocardial infarction, myocardial ischemia, nervous system disorder, peptic ulcer disease, peripheral arterial disease, peripheral vascular disease, stomach disorder, stroke disorder, vascular disorder | Recruiting | Not applicable | 2025-03-19 | NCT06541691 | |
| REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2024-06-25 | NCT01252953 | |
| Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2024-06-04 | NCT05202509 |